Latest Insider Transactions at Kintara Therapeutics, Inc. (KTRA)
This section provides a real-time view of insider transactions for Kintara Therapeutics, Inc. (KTRA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kintara Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kintara Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 18
2024
|
James A. Bianco Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,323,307
+50.0%
|
-
|
|
Jun 01
2023
|
Robert E. Hoffman President, CEO and Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
59,800
+46.46%
|
-
|
|
Jan 05
2023
|
Dennis M Brown Chief Scientific Officer |
BUY
Acquisition or disposition by will or laws
|
Direct |
363
+6.41%
|
-
|
|
Aug 01
2022
|
Anthony Scott Praill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,087
+46.41%
|
-
|
|
Aug 01
2022
|
Robert E. Hoffman President, CEO and Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
400,145
+46.78%
|
-
|
|
Aug 01
2022
|
Dennis M Brown Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,087
+49.3%
|
-
|
|
Feb 15
2022
|
Robert E. Hoffman President, CEO and Interim CFO |
BUY
Open market or private purchase
|
Direct |
55,000
+50.0%
|
$0
$0.47 P/Share
|
|
Dec 08
2021
|
Anthony Scott Praill Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
28,700
+43.56%
|
$0
$0.68 P/Share
|
|
Dec 07
2021
|
Saiid Zarrabian Head of Strategic Partnerships |
BUY
Open market or private purchase
|
Direct |
38,109
+40.71%
|
$0
$0.64 P/Share
|
|
Dec 06
2021
|
Saiid Zarrabian Head of Strategic Partnerships |
BUY
Open market or private purchase
|
Direct |
11,891
+40.61%
|
$0
$0.59 P/Share
|
|
Nov 22
2021
|
Laura L. Johnson Director |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$0
$0.74 P/Share
|
|
Apr 29
2021
|
Robert Joseph Toth Jr Director |
BUY
Conversion of derivative security
|
Direct |
325
+17.19%
|
-
|
|
Apr 29
2021
|
Robert Joseph Toth Jr Director |
BUY
Other acquisition or disposition
|
Direct |
3
+0.24%
|
-
|
|
Apr 29
2021
|
Anthony Scott Praill Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
938
+9.95%
|
-
|
|
Apr 29
2021
|
Anthony Scott Praill Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
8
+0.11%
|
-
|
|
Apr 29
2021
|
Dennis M Brown Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
750
+9.91%
|
-
|
|
Apr 29
2021
|
Dennis M Brown Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
6
+0.1%
|
-
|
|
Mar 31
2021
|
Anthony Scott Praill Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
22
+0.29%
|
-
|
|
Mar 31
2021
|
Dennis M Brown Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
17
+0.28%
|
-
|
|
Mar 31
2021
|
Robert Joseph Toth Jr Director |
BUY
Other acquisition or disposition
|
Direct |
8
+0.64%
|
-
|
|
Dec 31
2020
|
Anthony Scott Praill Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
22
+0.29%
|
-
|
|
Dec 31
2020
|
Robert Joseph Toth Jr Director |
BUY
Other acquisition or disposition
|
Direct |
8
+0.65%
|
-
|
|
Dec 31
2020
|
Dennis M Brown Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
17
+0.28%
|
-
|
|
Sep 30
2020
|
Dennis M Brown Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
17
+0.28%
|
-
|
|
Sep 30
2020
|
Anthony Scott Praill Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
22
+0.29%
|
-
|
|
Sep 30
2020
|
Robert Joseph Toth Jr Director |
BUY
Other acquisition or disposition
|
Direct |
8
+0.65%
|
-
|